Caption Management’s NewAmsterdam Pharma NAMS Stock Holding History

Caption Management’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.12M	Buy	92,200 +17,200	+23%	+$567K	0.01%	748
2026 Q1	$2.4M	Hold	75,000	–	–	0.01%	770
2025 Q4	$2.63M	Sell	75,000 -1,094,700	-94%	-$39.8M	0.02%	740
2025 Q3	$33.3M	Buy	1,169,700 +1,139,700	+3,799%	+$27.3M	0.26%	78
2025 Q2	$543K	Buy	+30,000	New	+$547K	0.01%	1092
2025 Q1	–	Sell	-199,900	Closed	-$5.14M	–	1859
2024 Q4	$5.14M	Buy	+199,900	New	+$4.25M	0.05%	361

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Caption Management's NAMS Position: Q2 2026 in Review

Caption Management sold out of NewAmsterdam Pharma (NAMS) in Q2 2026, closing a stake of 19,507 shares — an estimated $643K sold.

Caption Management first reported a position in NAMS in Q4 2024 and held it in 5 quarters. The position peaked at $3.72M in Q4 2024. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Caption Management reported no remaining NewAmsterdam Pharma position as of Q2 2026 after selling out during the quarter.
Caption Management sold 19,507 NewAmsterdam Pharma shares in Q2 2026, an estimated $643K.
Caption Management first reported a position in NewAmsterdam Pharma in Q4 2024 and held it in 5 quarters.
Caption Management's NewAmsterdam Pharma position peaked at $3.72M in Q4 2024.
195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.